首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2042521

一次性生物反應器市場：市場洞察、競爭格局及市場預測（2034 年）

Single-use Bioreactors - Market Insights, Competitive Landscape, and Market Forecast - 2034

出版日期: 2026年05月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

一次性生物反應器市場概述

全球一次性生物反應器市場規模預計將從 2025 年的 361382 億美元成長到 2034 年的 1511453 億美元，展現出強勁且持續的成長勢頭。
全球一次性生物反應器市場預計在 2026 年至 2034 年的預測期內將以 17.27% 的複合年成長率成長。
一次性生物反應器市場正受到生物製藥需求成長、成本效益以及生物製程技術進步等多重因素的強勁推動。單株抗體、疫苗、細胞和基因療法等生物製藥需求的不斷成長，促使人們對靈活、無菌的生產平台的需求日益增加，而一次性生物反應器系統在這些平台上表現出色。同時，這些生物反應器無需清洗、滅菌和大規模基礎設施，顯著降低了資本投資和營運成本，使其成為新興生物技術公司和合約研發生產機構（CDMO）的理想選擇。此外，生物製程的持續創新，包括規模化生產的改進、自動化程度的提高以及先進感測器整合技術的進步，正在提升生產效率和製程控制水準。這些因素共同推動了一次性生物反應器在研發和商業化生產中的應用，從而促進了市場的整體成長。
在一次性生物反應器市場中運作的主要公司包括 Sartorius AG、Thermo Fisher Scientific Inc.、Cytiva、Merck KGaA、Eppendorf SE、ABEC Inc.、PBS Biotech Inc.、Cellexus International Ltd.、Celltainer Biotech BV、Getinge AB、Solaris Biotech Srl. Inc.、Repligen Corporation 和 Corning Incorporated。
北美地區預計將成為一次性生物反應器市場的主要驅動力，這得益於其強大的生物製藥產業、先進生物製程技術的高普及率，以及賽默飛世爾科技公司（Thermo Fisher Scientific Inc.）、Cytiva公司和賽多利斯公司（Sartorius AG）等主要企業的強大影響力。此外，該地區還受益於大量的研發投入、完善的法規結構以及對生技藥品、疫苗、細胞和基因療法日益成長的需求。同時，合約研發生產機構（CDMO）和生物技術新創企業的不斷湧現，也進一步加速了靈活且經濟高效的一次性生物反應器系統的應用，從而推動了整體市場的成長。
在一次性生物反應器市場的產品類型細分中，預計到 2025 年，一次性生物反應器系統類別將佔最大的市場佔有率。

推動一次性生物反應器市場成長的因素

生物製藥需求的成長正推動一次性生物反應器需求的激增：單株抗體、疫苗、重組蛋白和基因療法等生物製藥需求的不斷成長是推動一次性生物反應器（SUB）市場發展的主要因素。這些治療方法需要靈活且無菌的生產系統，而一次性生物反應器正是理想選擇。
成本效益和資本投入減少：一次性生物反應器無需昂貴的不銹鋼基礎設施，從而顯著降低了整體成本和資本投入。由於無需進行清潔和滅菌流程，它們還減少了與人事費用、驗證和清潔劑相關的營運成本。此外，其一次性預滅菌的特性最大限度地減少了水、蒸氣和能源消耗等公用設施成本。總體而言，與傳統生物反應器相比，這些系統可將初始投資減少約 40%，使其成為尋求經濟高效且靈活的生產解決方案的新創公司和合約研發生產機構 (CDMO) 的理想選擇。
生物製程技術的進步：一次性生物反應器的持續創新顯著提高了生物製程效率，這主要得益於大型生物反應器設計的進步，目前系統的處理能力已超過5000公升。同時，自動化和數位化監控技術的整合實現了即時數據追蹤和更精確的運行控制。增強的感測器整合和先進的過程控制系統確保了對pH值、溫度和溶解氧等關鍵參數的更精確控制。這些進步的結合帶來了更高的生產力、更佳的產品均一性和擴充性，使得一次性生物反應器越來越適用於臨床和商業化生產。

一次性生物反應器市場報告細分

本一次性生物反應器市場報告全面概述了全球一次性生物反應器市場，揭示了關鍵趨勢、成長要素、挑戰和機會。該報告按產品類型、類型、細胞類型、分子類型、應用、最終用戶和地區對市場進行了分析。報告深入剖析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態。報告詳細介紹了主要產業參與企業的概況和近期產品創新，為企業提供關鍵數據，幫助其識別市場潛力、制定策略規劃，並把握快速成長的一次性生物反應器市場中的新興機會。

一次性生物反應器（SUB）是一種用於培養細胞和微生物以生產生物製藥（例如疫苗、單株抗體和重組蛋白）的一次性生物製程系統。由於它使用預滅菌的一次性塑膠袋代替傳統的不銹鋼容器，因此無需在不同批次之間進行清洗和滅菌。這使得一次性生物反應器更加靈活、經濟高效，尤其適用於研發、製程開發以及中小規模的生物製藥生產。

一次性生物反應器市場正受到生物製藥需求成長、成本效益以及生物製程技術持續進步等多重因素的強勁推動。單株抗體、疫苗、重組蛋白以及細胞和基因療法等生物製藥需求的不斷成長，顯著提升了對柔軟性、擴充性且無污染生產平台的需求，而一次性系統相比傳統的不銹鋼設備具有明顯的優勢。此外，這些生物反應器無需複雜的基礎設施、潔淨驗證和滅菌流程，從而顯著降低了資本投資和營運成本，使其成為新興生物技術公司、新創公司以及合約研發生產機構（CDMO）的理想選擇。

此外，生物製程的持續創新，包括大規模一次性系統（超過5000公升）的開發、自動化和數位化監控的整合以及先進感測器技術的運用，正在提升製程效率、即時控制和產品均一性。這些進步也有助於縮短前置作業時間，提高生產柔軟性，使企業能夠快速回應不斷變化的市場需求，並加快新治療方法的上市速度。這些因素共同推動了一次性生物反應器在研發、臨床和商業化生產各個階段的應用，從而顯著加速了整體市場成長。

一次性生物反應器市場的最新市場動態和趨勢是什麼？

生物製藥，尤其是單株抗體、疫苗、重組蛋白以及細胞和基因療法等先進治療方法的需求不斷成長，是推動一次性生物反應器（SUB）市場成長的最強勁動力之一。由於生物製藥具有高特異性和高效性，其在現代藥物研發管線中佔越來越重要的地位，因此製造商需要柔軟性、擴充性且無污染的生產系統，而一次性生物反應器恰好能夠高效地滿足這些需求。與傳統的不銹鋼系統不同，SUB無需在批次間進行清洗和滅菌，從而顯著減少了停機時間、運作成本和交叉污染的風險。這些特性對於高需求生物製藥和小批量個人化藥物的生產尤其重要。此外，依賴SUB快速擴大產能以因應生物製藥需求波動的合約研發生產機構（CDMO）的快速擴張也進一步推動了這一轉變。

近期發展進一步凸顯了生物製藥需求的成長如何推動技術進步和新產品的推出。例如，2025年3月，Cytiva（丹納赫集團旗下公司）擴展了其Xcellerex平台，新增了500公升和2000公升的大型一次性生物反應器，以滿足單株抗體和疫苗日益成長的生產需求。

此外，對成本效益和降低資本支出的日益關注是推動生物製藥生產中一次性生物反應器（SUB）普及的最強勁動力之一。傳統的不銹鋼生物反應器設施需要大量的初始投資，包括安裝、基礎設施、清洗系統、滅菌設備和驗證流程。相較之下，一次性生物反應器使用預滅菌的一次性袋，無需複雜的就地清洗（CIP）和原位滅菌（SIP）系統。這不僅顯著降低了初始資本支出（CAPEX），還降低了與水、能源、人事費用和維護相關的營運成本（OPEX）。研究表明，與傳統的不銹鋼工廠相比，一次性設施可將資本成本降低近40-50%，使其成為中小型生物技術公司和合約研發生產機構（CDMO）極具吸引力的選擇。例如，2025 年 4 月，藥明生物使用三個 5000 公升一次性生物反應器完成了商業規模的生產宣傳活動，這表明 CDMO 如何在避免對傳統設施進行大規模資本投資的同時，快速擴大生產能力。

因此，由於上述因素，預計一次性生物反應器市場在預測期內將整體擴張。

然而，塑膠廢棄物的產生、環境問題以及機械和操作方面的限制，共同限制一次性生物反應器市場的發展。一次性塑膠袋和塑膠管的廣泛使用增加了生物醫療廢棄物的產生量，尤其是在生產規模擴大後，這引發了永續性問題並增加了處置成本。同時，一次性系統的機械脆弱性，例如易受壓力影響、攪拌效率低以及抗剪切應力能力有限，會限制某些高需求或複雜細胞培養製程的最佳化和規模化。這些環境和技術方面的挑戰共同限制了一次性生物反應器在大規模、高產量生物製造設施中的全面應用，而這些設施對耐用性、效率和永續性有著至關重要的要求。

一次性生物反應器市場細分分析

按產品類型、類型、分子類型、應用程式、最終用戶和地區分類

一次性生物反應器市場區域分析

北美一次性生物反應器市場趨勢

預計到2025年，北美將佔一次性生物反應器市場34.75%的最大佔有率。北美預計將主導市場，主要得益於其強大的生物製藥產業、先進生物製程技術的高普及率，以及賽默飛世爾科技公司（Thermo Fisher Scientific Inc.）、Cytiva和賽多利斯公司（Sartorius AG）等領先企業的強大影響力。此外，該地區還受益於大量的研發投入、完善的法律規範以及對生技藥品、疫苗、細胞和基因療法日益成長的需求。同時，合約研發生產機構（CDMO）和生物技術新創企業的不斷湧現，進一步加速了靈活且經濟高效的一次性系統的普及，從而推動了整體市場成長。

同時，先進的攪拌器設計、改進的氧氣傳輸系統、整合感測器和自動化數位生物生物製程平台等技術創新正在提升製程效率、可擴展性和產品均一性，進一步加速了該地區的普及應用。北美主導的地位得益於賽默飛世爾科技、Cytiva（丹納赫旗下公司）和賽多利斯等關鍵公司不斷擴大的一次性產品組合，以及對生物製藥、疫苗和細胞基因療法的大力投資。例如，賽默飛世爾科技於2025年推出了一款增強型一次性生物反應器系統，該系統具備新一代自動化功能，旨在提高可擴展性和生產效率。 2025年3月，Cytiva擴展了其Xcellerex平台，推出了高容量一次性生物反應器，以滿足臨床和商業生產階段的靈活生產需求。

因此，由於上述因素，預計全部區域一次性生物反應器市場將在預測期內擴張。

歐洲一次性生物反應器市場趨勢

歐洲一次性生物反應器市場正經歷強勁且持續的成長，這主要得益於該地區成熟的生物製藥產業、先進生物製藥生產技術的日益普及以及對靈活且無污染生產系統的強力的監管支持。德國、英國、法國和瑞士等歐洲國家是生物製藥、疫苗以及細胞和基因療法研發的重要中心，這推動了一次性技術在臨床和商業生產中的快速應用。賽多利斯（Sartorius）、默克集團（Merck KGaA）、Cytiva 和賽默飛世爾科技（Thermo Fisher Scientific）等領先企業的存在進一步鞏固了該地區的生態系統，因為這些公司不斷部署先進的攪拌式和模組化一次性生物反應器平台，以支持可擴展的生產。此外，歐洲對基於病毒載體的基因療法和 CAR-T 細胞療法的需求不斷成長，也促使人們青睞一次性生物反應器，因為其具有封閉系統設計、降低污染風險和縮短批次處理時間等優勢。

近期發展進一步凸顯了這一成長動能。 2023年，歐盟委員會根據「載體製造舉措」撥款1.8億歐元，用於擴大符合GMP標準的生物製造能力，並明確支持全部區域用於生產病毒載體和細胞療法的單次使用平台。

因此，由於上述因素，預計歐洲一次性生物反應器市場在預測期內將持續擴張。

亞太地區一次性生物反應器市場趨勢

亞太地區正崛起為一次性生物反應器市場的主要驅動力，這主要得益於生物製藥行業的快速擴張、政府對生物技術發展的支持力度加大以及對生技藥品生產基礎設施投資的擴充性。中國、印度、日本和韓國等國家在疫苗生產、單株抗體研發和生物相似藥生產方面均實現了強勁成長，而這些領域都高度依賴一次性生物反應器技術，因為該技術具有柔軟性、成本效益和可擴展性等優點。此外，該地區也受惠於越來越多的合約研發生產機構（CDMO）採用一次性系統來滿足全球對臨床和商業生物製藥生產的外包需求。更重要的是，自新冠疫情爆發以來，各國政府推出的有利於國內疫苗生產和生物製藥自給自足的政策，顯著加速了先進生物製程平台的應用。

近期發展進一步凸顯了這一勢頭。 2024年6月，藥明生物在中國擴大了一次性生物反應器產能，新增了數條5000公升生產線。這增強了其大規模生物製藥生產能力，並增加了上游工程中對一次性系統的需求。

因此，由於上述因素，預計在預測期內，歐洲一次性生物反應器市場整體將擴大。

一次性生物反應器市場的主要參與者有哪些公司？

以下是單次使用生物反應器市場的主要參與者。這些公司合計佔最大的市場佔有率，並引領產業趨勢。

Sartorius AG
Thermo Fisher Scientific Inc.
Cytiva
Merck KGaA
Eppendorf SE
ABEC Inc.
PBS Biotech Inc.
Cellexus International Ltd.
Celltainer Biotech BV
Getinge AB
Solaris Biotech Solutions Srl
Pierre Guerin SAS
Meissner Filtration Products Inc.
Entegris Inc.
Avantor Inc.
Repligen Corporation
Corning Incorporated
其他

競爭格局對一次性生物反應器市場有何影響？

一次性生物反應器市場的競爭格局日益動態化和集中化，這主要由少數幾家全球領先的生物製程公司之間的激烈競爭和持續的技術創新所塑造。賽默飛世爾科技、丹納赫（Cytiva）、賽多利斯和默克集團等主要企業憑藉其豐富的產品系列、全球生產網路以及對下一代生物反應器技術的持續投入，主導著市場。推動市場競爭的主要動力在於，需要提供可擴展、自動化且數位化整合的一次性系統，以支援生物製藥研發和企業發展的加速。各公司越來越注重策略聯盟、併購能擴張，以增強生物製程能力並擴大其地理覆蓋範圍。例如，到2025年，賽默飛世爾科技（Thermo Fisher Scientific）透過大規模收購和平台整合策略擴展了其生物製程系統，以增強其上游和下游能力；同時，Cytiva和Zartrius繼續在北美和歐洲擴展其攪拌槽和模組化一次性生物反應器平台，以支持高需求生物製藥的生產。此外，亞太地區的新興企業和區域製造商正透過提供經濟高效的客製化解決方案，特別是針對合約研發生產機構（CDMO）和當地生物製藥公司的解決方案，加劇競爭。技術創新、策略整合和區域擴張的結合，造就了競爭異常激烈的市場格局，各公司都致力於提高效率、擴充性和端到端的生物製程解決方案，以獲得市場主導地位。

一次性生物反應器市場的最新發展趨勢

2026 年 2 月，賽默飛世爾科技推出了一款 5 公升 DynaDrive 一次性生物反應器，用於小規模和學術研究中符合 GMP 標準的生物製程，從而擴大了生物製造技術的普及範圍。
2025 年 4 月，AGC Biologics 宣布擴建位於日本橫濱的工廠，新增兩台 5,000 公升 Thermo Scientific DynaDrive 一次性生物反應器，無需進行大規模不銹鋼基礎設施升級即可實現大規模生物製劑生產。
2025 年 4 月，藥明生物使用三個 5000 公升一次性生物反應器完成了商業規模的生產宣傳活動，證明了 CDMO 如何在避免對傳統設施進行大規模資本投資的同時，快速擴大生產能力。

一次性生物反應器市場的市場區隔

按產品類型分類的一次性生物反應器市場趨勢
一次性生物反應器系統
10公升或以下
11～100 L
101～500 L
501～1500 L
1500公升或以上
一次性媒體袋
2D包
3D袋
過濾過濾組件
其他配件
按類型分類的一次性生物反應器
攪拌罐式一次性生物反應器
波式（振盪式）生物反應器
其他
一次性生物反應器細胞類型暴露
哺乳動物
細菌
其他
一次性生物反應器分子類型應用
單株抗體（mAbs）
疫苗
重組蛋白
其他
一次性生物反應器的使用現狀
研究與發展（R&D）
生物生產/商業化生產
接觸一次性生物反應器終端用戶
製藥和生物製藥公司
合約研究組織（CRO）
合約研發生產組織（CDMO/CMO）
學術和研究機構
一次性生物反應器的區域趨勢
北美一次性生物反應器市場
美國一次性生物反應器市場
加拿大一次性生物反應器市場
墨西哥一次性生物反應器市場
歐洲一次性生物反應器市場
英國一次性生物反應器市場
德國一次性生物反應器市場
法國一次性生物反應器市場
義大利一次性生物反應器市場
西班牙一次性生物反應器市場
其他歐洲一次性生物反應器市場
亞太地區一次性生物反應器市場
中國一次性生物反應器市場
日本一次性生物反應器市場
印度的單次使用生物反應器市場
澳洲一次性生物反應器市場
韓國一次性生物反應器市場
亞太地區其他一次性生物反應器市場
世界其他地區的單次使用生物反應器市場
南美洲一次性生物反應器市場
中東一次性生物反應器市場
非洲一次性生物反應器市場

影響分析

人工智慧驅動的創新與應用：

人工智慧驅動的創新正日益改變一次性生物反應器（SUB）的使用方式，使生物製程更加可預測、自動化和高效。人工智慧不再僅依賴人工監控和固定的程式參數，而是能夠在整個上游生物製造過程中實現即時決策、製程最佳化和品管。

人工智慧的主要應用之一是預測性流程最佳化。機器學習模型分析歷史和即時生物過程數據（pH值、溶解氧、營養濃度、細胞密度），預測最佳生長條件，從而最大限度地提高單株抗體和疫苗等生物製藥產品的產量。人工智慧也廣泛應用於異常檢測和污染預測，演算法持續監測感測器數據，及早發現偏差，降低批次失敗風險，提高產品均一性。在先進的一次性系統中，人工智慧輔助自動化控制迴路，動態調節流體供應速率、通氣量和溫度，無需人工干預即可維持理想的細胞培養條件。

另一項重大創新是將人工智慧與生物反應器的數位雙胞胎結合。在這種模式下，一次性系統的虛擬模型可以即時模擬細胞培養行為。這使得科學家能夠在實際應用各種製程條件之前對其進行數位化測試，從而縮短開發時間並降低成本。企業也正在利用人工智慧進行規模化建模，透過預測細胞在規模轉換過程中的行為，幫助彌合實驗室規模（例如 10-500 公升）和商業規模生物反應器之間的差距。

此外，人工智慧透過分析複雜的多感測器資料流來增強製程分析技術（PAT），從而在封閉式一次性生物反應器環境中實現更智慧的回饋控制系統。這在連續培養和灌流培養等生物製程中尤其重要，因為這些製程需要在較長的生產週期內精確控制條件。

總體而言，人工智慧正在將一次性生物反應器轉變為智慧的、自我最佳化的生物製造系統，從而提高生產力，減少人為錯誤，降低成本，並加速下一代生技藥品、疫苗以及細胞和基因療法的開發。

美國關稅對一次性生物反應器市場的影響分析：

對美國關稅對一次性生物反應器市場影響的分析表明，需求不會直接下降，但會對定價、供應鏈和生產決策產生中等程度但具有戰略意義的影響。一次性生物反應器屬於生物製程和醫療/工業設備供應鏈，其中許多供應鏈依賴進口組件，例如生物製程袋、感測器、管路系統、過濾器和控制系統，尤其來自歐洲和亞洲。因此，美國對醫療設備、實驗室設備或工業生物製程組件提高關稅可能會推高北美製造商的投入成本。這可能導致一次性系統的生產成本上升，終端用戶（生物製藥公司和合約研發生產機構）面臨更大的價格壓力，並導致採購決策短期延遲。然而，強大的美國國內製造業基礎在一定程度上抵消了這種影響，例如賽默飛世爾科技、Cytiva（丹納赫旗下公司）和默克等公司在當地設有生產設施，並減少了對進口的依賴。此外，關稅通常會促進供應鏈本地化，並增加對美國生物製造能力的投資，從而增強市場的長期韌性。近期的一些進展，例如美國商務部計劃於2025年對醫療設備進口（包括根據「貿易法」第232條進行審查的生物製造相關設備）展開調查，凸顯了未來關稅調整的可能性，這可能會進一步影響籌資策略，並促進生物程序設備的國內生產。總體而言，雖然關稅可能會暫時增加成本和供應鏈的複雜性，但它們也在加速本地化趨勢，並鞏固北美在先進生物製程技術（包括一次性生物反應器）領域的領先地位。

這項分析能為客戶帶來哪些好處？

成本管理：透過了解關稅趨勢，客戶可以預測成本上漲，並據此調整定價策略，以確保盈利。
供應鏈最佳化：透過尋找替代來源並實現供應鏈多元化，客戶可以減少對高關稅地區的依賴，增強自身抵禦能力。
監管合規：專家指導幫助客戶應對不斷變化的法規環境，從而保持合規並避免潛在的法律挑戰。
策略規劃：深入了解關稅的影響，使客戶能夠就製造地、夥伴關係和打入市場策略做出明智的決策。

一次性生物反應器市場報告要點

目前一次性生物反應器市場規模分析（2025 年）及 8 年市場預測（2026-2034 年）
過去三年發生的主要產品和技術開發、併購、合作和合資企業
主導一次性生物反應器市場的領導公司。
一次性生物反應器市場的其他競爭者也面臨各種機會。
哪些細分市場在2025年表現最佳？這些細分市場在2034年的表現又會如何？
目前哪些地區和國家在一次性生物反應器市場表現最佳？
為了在一次性生物反應器市場尋求未來的成長機會，企業應該專注於哪些地區和國家？

關於一次性生物反應器市場的常見問題

1. 一次性生物反應器市場的成長率是多少？

預計從 2026 年到 2034 年的預測期內，一次性生物反應器市場將以 17.27% 的複合年成長率成長。

2. 一次性生物反應器的市場需求是什麼？

全球一次性生物反應器市場預計將從 2025 年的 361382 億美元成長到 2034 年的 1511453 億美元。

3. 一次性生物反應器市場中，哪個地區佔最大的市佔率？

北美地區預計將成為一次性生物反應器市場的主要驅動力，這得益於其強大的生物製藥產業、先進生物製程技術的高普及率，以及賽默飛世爾科技公司（Thermo Fisher Scientific Inc.）、Cytiva公司和賽多利斯公司（Sartorius AG）等主要企業的強大影響力。此外，該地區還受益於大量的研發投入、完善的法規結構以及對生技藥品、疫苗、細胞和基因療法日益成長的需求。同時，合約研發生產機構（CDMO）和生物技術新創企業的不斷湧現，也進一步加速了靈活且經濟高效的一次性生物反應器系統的應用，從而推動了整體市場的成長。

4. 一次性生物反應器市場的成長要素是什麼？

一次性生物反應器市場正受到生物製藥需求成長、成本效益以及生物製程技術進步等多重因素的強勁推動。單株抗體、疫苗、細胞和基因療法等生物製藥需求的不斷成長，促使人們對靈活、無菌的生產平台的需求日益增加，而一次性生物反應器系統在這些平台上表現出色。同時，這些生物反應器無需清洗、滅菌和大規模基礎設施，顯著降低了資本投資和營運成本，使其成為新興生物技術公司和合約研發生產機構（CDMO）的理想選擇。此外，生物製程的持續創新，包括可擴展性的提升、自動化程度的提高以及先進感測器整合技術的進步，正在增強生產效率和製程控制能力。這些因素共同推動了一次性生物反應器在研發和商業化生產中的應用，從而促進了市場的整體成長。

5. 一次性生物反應器市場的主要企業有哪些？

一次性生物反應器市場的主要參與企業包括 Sartorius AG、Thermo Fisher Scientific Inc.、Cytiva、Merck KGaA、Eppendorf SE、ABEC Inc.、PBS Biotech Inc.、Cellexus International Ltd.、Celltainer Biotech BV、Getinge AB、Solaris Biotech of Srl、Pierre Guili Products. Corporation 和 Corning Incorporated。

The global Single-use bioreactors market is expected to increase from USD 3,613.82 million in 2025 to USD 15,114.53 million by 2034, reflecting strong and sustained growth.
The global Single-use bioreactors market is growing at a CAGR of 17.27% during the forecast period from 2026 to 2034.
The single-use bioreactors market is being strongly driven by the combined impact of rising demand for biopharmaceuticals, cost efficiency, and technological advancements in bioprocessing. The growing need for biologics such as monoclonal antibodies, vaccines, and cell & gene therapies is increasing the demand for flexible and sterile manufacturing platforms, where single-use systems are highly effective. At the same time, these bioreactors significantly reduce capital investment and operational costs by eliminating cleaning, sterilization, and large infrastructure requirements, making them especially attractive for emerging biotech firms and CDMOs. Additionally, continuous innovations in bioprocessing, such as improved scalability, automation, and advanced sensor integration, are enhancing productivity and process control. Together, these factors are accelerating the adoption of single-use bioreactors across R&D and commercial manufacturing, thereby boosting overall market growth.
The leading companies operating in the single-use bioreactors market include Sartorius AG, Thermo Fisher Scientific Inc., Cytiva, Merck KGaA, Eppendorf SE, ABEC Inc., PBS Biotech Inc., Cellexus International Ltd., Celltainer Biotech BV, Getinge AB, Solaris Biotech Solutions S.r.l., Pierre Guerin SAS, Meissner Filtration Products Inc., Entegris Inc., Avantor Inc., Repligen Corporation, Corning Incorporated, and others.
North America is expected to dominate the single-use bioreactors market due to its strong biopharmaceutical industry, high adoption of advanced bioprocessing technologies, and significant presence of key players such as Thermo Fisher Scientific Inc., Cytiva, and Sartorius AG. The region also benefits from substantial R&D investments, a well-established regulatory framework, and increasing demand for biologics, vaccines, and cell & gene therapies. Additionally, the growing number of CDMOs and biotechnology startups further accelerates the adoption of flexible and cost-effective single-use systems, supporting overall market growth.
In the product type segment of the single-use bioreactors market, the single-use bioreactor system category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Single-use Bioreactors Market

Rising demand for biopharmaceuticals leading to a surge in single-use bioreactors: The increasing demand for biologics such as monoclonal antibodies, vaccines, recombinant proteins, and gene therapies is the primary driver of the SUB market. These therapies require flexible and sterile manufacturing systems, making single-use bioreactors highly suitable.
Cost efficiency and lower capital investment: Single-use bioreactors significantly reduce overall costs by eliminating the need for expensive stainless-steel infrastructure, thereby lowering capital expenditure. They also remove the requirement for cleaning and sterilization processes, which reduces operational expenses related to labor, validation, and cleaning agents. In addition, utility costs such as water, steam, and energy consumption are minimized due to their disposable and pre-sterilized nature. Overall, these systems can lower initial investment by approximately 40% compared to traditional bioreactors, making them highly attractive for startups and contract development and manufacturing organizations (CDMOs) seeking cost-efficient and flexible production solutions.
Technological advancements in bioprocessing: Continuous innovations in single-use bioreactors are significantly improving bioprocessing efficiency through advancements in large-scale bioreactor design, with systems now reaching capacities of 5000L and beyond. At the same time, the integration of automation and digital monitoring technologies allows for real-time data tracking and improved operational control. Enhanced sensor integration and advanced process control systems further ensure precise regulation of critical parameters such as pH, temperature, and dissolved oxygen. Together, these advancements lead to higher productivity, improved consistency in output, and greater scalability, making single-use bioreactors increasingly suitable for both clinical and commercial manufacturing.

Single-use Bioreactors Market Report Segmentation

This single-use bioreactors market report offers a comprehensive overview of the global single-use bioreactors market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Products Type (Single-use Bioreactor System { Up to 10 L, 11-100 L, 101-500 L, 501-1500 L, and Above 1500 L}, Single-use Media Bags {2D bags and 3D bags}, Single-use Filtration Assemblies, and Other Accessories), Type (Stirred-tank Single-use Bioreactors, Wave-induced (rocking motion) Bioreactors, and Others), Cell Type (Mammalian, Bacterial, and Others), Molecule Type (Monoclonal antibodies (mAbs), Vaccines, Recombinant Proteins, and Others), Application (Research & Development (R&D) and Bioproduction / Commercial Manufacturing), End-Users (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations (CROs), Contract Development & Manufacturing Organizations (CDMOs/CMOs), and Academic & Research Institutes), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Single-use Bioreactors market.

A single-use bioreactor (SUB) is a disposable bioprocessing system used to grow cells or microorganisms for the production of biologics such as vaccines, monoclonal antibodies, and recombinant proteins. Instead of traditional stainless-steel vessels, it uses pre-sterilized, single-use plastic bags, eliminating the need for cleaning and sterilization between batches. This makes single-use bioreactors more flexible, cost-effective, and efficient, particularly for research, process development, and small- to mid-scale biopharmaceutical manufacturing.

The single-use bioreactors market is being strongly driven by the combined impact of rising demand for biopharmaceuticals, cost efficiency, and continuous technological advancements in bioprocessing. The increasing need for biologics such as monoclonal antibodies, vaccines, recombinant proteins, and cell & gene therapies is significantly boosting the demand for flexible, scalable, and contamination-free manufacturing platforms, where single-use systems offer clear advantages over traditional stainless-steel setups. In addition, these bioreactors substantially reduce capital investment and operational costs by eliminating the need for complex infrastructure, cleaning validation, and sterilization processes, making them particularly attractive for emerging biotech companies, startups, and contract development and manufacturing organizations (CDMOs).

Furthermore, ongoing innovations in bioprocessing, such as the development of large-scale single-use systems (up to 5000L and beyond), integration of automation and digital monitoring, and advanced sensor technologies, are improving process efficiency, real-time control, and product consistency. These advancements also support faster turnaround times and greater manufacturing flexibility, enabling companies to respond quickly to changing market demands and accelerate time-to-market for new therapies. Collectively, these factors are driving widespread adoption of single-use bioreactors across research, clinical, and commercial production stages, thereby significantly boosting overall market growth.

What are the latest Single-use Bioreactors market dynamics and trends?

The rising demand for biopharmaceuticals, particularly monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies such as cell and gene therapies, is one of the strongest drivers accelerating the growth of the single-use bioreactor (SUB) market. As biologics increasingly dominate modern drug pipelines due to their high specificity and efficacy, manufacturers require flexible, scalable, and contamination-free production systems, which single-use bioreactors efficiently provide. Unlike traditional stainless-steel systems, SUBs eliminate the need for cleaning and sterilization between batches, significantly reducing downtime, operational costs, and risk of cross-contamination, features that are especially critical in high-demand biologics manufacturing and small-batch personalized medicine. This shift is further reinforced by the rapid expansion of contract development and manufacturing organizations (CDMOs), which rely on SUBs to quickly scale production capacity in response to fluctuating biopharma demand.

Recent developments further highlight how rising biopharmaceutical demand is translating into technological expansion and product launches. For instance, in March 2025, Cytiva (Danaher) expanded its Xcellerex platform with large-scale 500 L and 2,000 L single-use bioreactors to support increasing monoclonal antibody and vaccine production needs.

Additionally, the growing focus on cost efficiency and lower capital investment is one of the most powerful drivers accelerating the adoption of single-use bioreactors (SUBs) in biopharmaceutical manufacturing. Traditional stainless-steel bioreactor facilities require heavy upfront investment for installation, infrastructure, cleaning systems, sterilization units, and validation processes. In contrast, single-use bioreactors use pre-sterilized disposable bags, eliminating the need for complex cleaning-in-place (CIP) and sterilization-in-place (SIP) systems. This significantly reduces initial capital expenditure (CAPEX) and also lowers operational expenditure (OPEX) related to water, energy, labor, and maintenance. Studies show that single-use-based facilities can reduce capital costs by nearly 40-50% compared to conventional stainless-steel plants, making them highly attractive for small and mid-sized biotech firms as well as contract development and manufacturing organizations (CDMOs). For instance, in April 2025, WuXi Biologics completed commercial-scale production campaigns using three 5,000 L single-use bioreactors, demonstrating how CDMOs are scaling capacity rapidly while avoiding massive capital investments in traditional facilities.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors during the forecast period.

However, plastic waste generation and environmental concerns, along with mechanical and operational limitations, collectively act as significant restraints for the single-use bioreactor market. The extensive use of disposable plastic bags and tubing leads to a growing volume of biomedical waste, raising sustainability issues and increasing disposal costs, especially as production scales up. At the same time, the mechanical fragility of single-use systems, such as sensitivity to pressure, mixing inefficiencies, and limited tolerance to shear stress, can restrict process optimization and scalability for certain high-demand or complex cell cultures. Together, these environmental and technical challenges limit full-scale adoption of single-use bioreactors in large, high-volume biomanufacturing facilities, where durability, efficiency, and sustainability are critical requirements.

Single-use Bioreactors Market Segment Analysis

Single-use Bioreactors Market by Products Type (Single-use Bioreactor System {Up to 10 L, 11-100 L, 101-500 L, 501-1500 L, and Above 1500 L}, Single-use Media Bags {2D bags and 3D bags}, Single-use Filtration Assemblies, and Other Accessories), Type (Stirred-tank Single-use Bioreactors, Wave-induced (rocking motion) Bioreactors, and Others), Cell Type (Mammalian, Bacterial, and Others), Molecule Type (Monoclonal antibodies (mAbs), Vaccines, Recombinant Proteins, and Others), Application (Research & Development (R&D) and Bioproduction / Commercial Manufacturing), End-Users (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations (CROs), Contract Development & Manufacturing Organizations (CDMOs/CMOs), and Academic & Research Institutes), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Single-use Bioreactors Market Regional Analysis

North America Single-use Bioreactors Market Trends

North America is expected to account for the highest proportion of 34.75% of the single-use bioreactors market in 2025, out of all regions. North America is expected to dominate the single-use bioreactors market due to its strong biopharmaceutical industry, high adoption of advanced bioprocessing technologies, and significant presence of key players such as Thermo Fisher Scientific Inc., Cytiva, and Sartorius AG. The region also benefits from substantial R&D investments, a well-established regulatory framework, and increasing demand for biologics, vaccines, and cell & gene therapies. Additionally, the growing number of CDMOs and biotechnology startups further accelerates the adoption of flexible and cost-effective single-use systems, supporting overall market growth.

At the same time, technological innovations such as advanced stirred-tank designs, improved oxygen transfer systems, integrated sensors, and automation-enabled digital bioprocessing platforms are enhancing process efficiency, scalability, and product consistency, further driving adoption in the region. North America's leadership is reinforced by strong investments in biologics, vaccines, and cell and gene therapies, supported by major players like Thermo Fisher Scientific, Cytiva (Danaher), and Sartorius, expanding their single-use portfolios. For example, in 2025, Thermo Fisher introduced enhanced single-use bioreactor systems integrated with next-generation automation for improved scalability and productivity. In March 2025, Cytiva expanded its Xcellerex platform with higher-capacity single-use bioreactors to support flexible manufacturing needs across clinical and commercial production stages.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors across the region during the forecast period.

Europe Single-use Bioreactors Market Trends

The Single-use Bioreactors market in Europe is witnessing strong and sustained growth due to the region's well-established biopharmaceutical industry, increasing adoption of advanced biologics manufacturing technologies, and strong regulatory support for flexible and contamination-free production systems. European countries such as Germany, the UK, France, and Switzerland are major hubs for biologics, vaccines, and cell and gene therapy development, which is driving the rapid adoption of single-use technologies in both clinical and commercial manufacturing. The presence of leading companies like Sartorius, Merck KGaA, Cytiva, and Thermo Fisher Scientific further strengthens the regional ecosystem, as these players continuously introduce advanced stirred-tank and modular single-use bioreactor platforms to support scalable production. Additionally, Europe is experiencing growing demand for viral vector-based gene therapies and CAR-T cell therapies, where single-use bioreactors are preferred due to their closed-system design, reduced contamination risk, and faster batch turnaround times.

Recent developments further highlight this growth momentum. In 2023, the European Commission allocated €180 million under its Vector Manufacturing Initiative to expand GMP biomanufacturing capacity, explicitly supporting single-use platforms for viral vector and cell therapy production across the region.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors in Europe during the forecast period.

Asia-Pacific Single-use Bioreactors Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the single-use bioreactors market due to the rapid expansion of the biopharmaceutical industry, increasing government support for biotechnology development, and rising investments in biologics manufacturing infrastructure. Countries such as China, India, Japan, and South Korea are witnessing strong growth in vaccine production, monoclonal antibody development, and biosimilar manufacturing, all of which rely heavily on single-use bioreactor technologies for their flexibility, cost efficiency, and scalability. The region is also benefiting from the growing presence of contract development and manufacturing organizations (CDMOs), which are adopting single-use systems to meet global outsourcing demand for clinical and commercial biologics production. Additionally, favorable government initiatives promoting local vaccine manufacturing and biopharma self-sufficiency-especially after the COVID-19 pandemic-have significantly accelerated the adoption of advanced bioprocessing platforms.

Recent developments further highlight this momentum. In June 2024, WuXi Biologics expanded its single-use bioreactor capacity in China by adding multiple 5,000 L production lines, strengthening large-scale biologics manufacturing capabilities, and reinforcing demand for upstream single-use systems.

Thus, the factors mentioned above are expected to boost the overall market of single-use bioreactors across Europe during the forecast period.

Who are the major players in the single-use bioreactors market?

The following are the leading companies in the single-use bioreactors market. These companies collectively hold the largest market share and dictate industry trends.

Sartorius AG
Thermo Fisher Scientific Inc.
Cytiva
Merck KGaA
Eppendorf SE
ABEC Inc.
PBS Biotech Inc.
Cellexus International Ltd.
Celltainer Biotech BV
Getinge AB
Solaris Biotech Solutions S.r.l.
Pierre Guerin SAS
Meissner Filtration Products Inc.
Entegris Inc.
Avantor Inc.
Repligen Corporation
Corning Incorporated
Others

How is the competitive landscape shaping the single-use bioreactors market?

The competitive landscape of the single-use bioreactors market is becoming increasingly dynamic and consolidated, shaped by strong rivalry among a few global bioprocessing leaders and continuous technological innovation. Major players such as Thermo Fisher Scientific, Danaher (Cytiva), Sartorius AG, and Merck KGaA dominate the market through extensive product portfolios, global manufacturing networks, and continuous investment in next-generation bioreactor technologies. Competition is largely driven by the need to offer scalable, automated, and digitally integrated single-use systems that support faster biologics development and commercial production. Companies are increasingly focusing on strategic collaborations, mergers and acquisitions, and capacity expansions to strengthen their bioprocessing capabilities and expand geographic reach. For example, in 2025, Thermo Fisher Scientific expanded its bioprocessing ecosystem through major acquisitions and platform integration strategies to enhance upstream and downstream capabilities, while Cytiva and Sartorius continued to expand their stirred-tank and modular single-use bioreactor platforms in North America and Europe to support high-demand biologics production. At the same time, emerging players and regional manufacturers in the Asia Pacific are intensifying competition by offering cost-effective and customized solutions, particularly for CDMOs and local biopharma companies. This combination of technological innovation, strategic consolidation, and regional expansion is making the competitive landscape highly active, with companies focusing on improving efficiency, scalability, and end-to-end bioprocessing solutions to gain market advantage.

Recent Developmental Activities in the Single-use Bioreactors Market

In February 2026, Thermo Fisher Scientific introduced the 5 L DynaDrive single-use bioreactor aimed at small-scale and academic GMP-ready bioprocessing, enabling broader access to biomanufacturing technologies.
In April 2025, AGC Biologics announced an expansion of its Yokohama facility in Japan by installing two 5,000 L Thermo Scientific DynaDrive single-use bioreactors, enabling large-scale biologics production without the need for extensive stainless-steel infrastructure upgrades.
In April 2025, WuXi Biologics completed commercial-scale production campaigns using three 5,000 L single-use bioreactors, demonstrating how CDMOs are scaling capacity rapidly while avoiding massive capital investments in traditional facilities.

Single-use Bioreactors Market Segmentation

Single-use Bioreactors by Product Type Exposure
Single-use Bioreactor Systems
Up to 10 L
11-100 L
101-500 L
501-1500 L
Above 1500 L
Single-use Media Bags
2D bags
3D bags
Single-use Filtration Assemblies
Other Accessories
Single-use Bioreactors Type Exposure
Stirred-tank Single-use Bioreactors
Wave-induced (rocking motion) Bioreactors
Others
Single-use Bioreactors Cell Type Exposure
Mammalian
Bacterial
Others
Single-use Bioreactors Molecule Type Exposure
Monoclonal antibodies (mAbs)
Vaccines
Recombinant proteins
Others
Single-use Bioreactors Application Exposure
Research & Development (R&D)
Bioproduction / Commercial Manufacturing
Single-use Bioreactors End-Users Exposure
Pharmaceutical & biopharmaceutical companies
Contract Research Organizations (CROs)
Contract Development & Manufacturing Organizations (CDMOs/CMOs)
Academic & Research Institutes
Single-use Bioreactors Geography Exposure
North America Single-use Bioreactors Market
United States Single-use Bioreactors Market
Canada Single-use Bioreactors Market
Mexico Single-use Bioreactors Market
Europe Single-use Bioreactors Market
United Kingdom Single-use Bioreactors Market
Germany Single-use Bioreactors Market
France Single-use Bioreactors Market
Italy Single-use Bioreactors Market
Spain Single-use Bioreactors Market
Rest of Europe Single-use Bioreactors Market
Asia-Pacific Single-use Bioreactors Market
China Single-use Bioreactors Market
Japan Single-use Bioreactors Market
India Single-use Bioreactors Market
Australia Single-use Bioreactors Market
South Korea Single-use Bioreactors Market
Rest of Asia-Pacific Single-use Bioreactors Market
Rest of the World Single-use Bioreactors Market
South America Single-use Bioreactors Market
Middle East Single-use Bioreactors Market
Africa Single-use Bioreactors Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are increasingly reshaping single-use bioreactors (SUBs) by making bioprocessing more predictive, automated, and efficient. Instead of relying only on manual monitoring and fixed process parameters, AI enables real-time decision-making, process optimization, and quality control across upstream biomanufacturing.

One major application is predictive process optimization, where machine learning models analyze historical and real-time bioprocess data (pH, dissolved oxygen, nutrient levels, and cell density) to predict optimal growth conditions and maximize yield of biologics such as monoclonal antibodies and vaccines. AI is also widely used in anomaly detection and contamination prediction, where algorithms continuously monitor sensor data to detect deviations early, reducing batch failure risks and improving product consistency. In advanced single-use systems, AI supports automated control loops, adjusting feeding rates, aeration, and temperature dynamically to maintain ideal cell culture conditions without human intervention.

Another key innovation is the integration of AI with digital twins of bioreactors, where a virtual model of the single-use system simulates cell culture behavior in real time. This helps scientists test different process conditions digitally before applying them physically, reducing development time and cost. Companies are also using AI for scale-up modeling, helping bridge the gap between laboratory-scale (e.g., 10-500 L) and commercial-scale bioreactors by predicting how cells will behave during scale transitions.

In addition, AI is enhancing process analytical technology (PAT) by interpreting complex multi-sensor data streams, enabling smarter feedback control systems in closed single-use bioreactor environments. This is particularly valuable in continuous and perfusion-based bioprocessing, where conditions must be tightly controlled over long production cycles.

Overall, AI is transforming single-use bioreactors into intelligent, self-optimizing biomanufacturing systems, improving productivity, reducing human error, lowering costs, and accelerating the development of next-generation biologics, vaccines, and cell and gene therapies.

U.S. Tariff Impact Analysis on Single-use Bioreactors Market:

The U.S. tariff impact analysis on the single-use bioreactors market indicates a moderate but strategically significant influence on pricing, supply chains, and manufacturing decisions rather than a direct demand reduction. Single-use bioreactors are classified under bioprocessing and medical/industrial equipment supply chains, many of which depend on imported components such as bioprocess bags, sensors, tubing systems, filters, and control systems, particularly from Europe and Asia. As a result, any U.S. tariff increases on medical devices, laboratory equipment, or industrial bioprocessing components can raise input costs for manufacturers operating in North America. This leads to higher production costs for single-use systems, increased pricing pressure on end users (biopharma companies and CDMOs), and potential short-term delays in procurement decisions. However, the impact is partially offset by the strong domestic manufacturing base in the U.S., where companies like Thermo Fisher Scientific, Cytiva (Danaher), and Merck have local production facilities, reducing reliance on imports. Additionally, tariffs often encourage regionalization of supply chains and increased investment in U.S.-based biomanufacturing capacity, strengthening long-term market resilience. Recent policy developments, such as U.S. Commerce Department investigations in 2025 into medical equipment imports (including biomanufacturing-related tools under Section 232 trade reviews), highlight potential future tariff adjustments that could further influence sourcing strategies and encourage domestic production of bioprocessing equipment. Overall, while tariffs may temporarily increase costs and supply chain complexity, they are also accelerating localization trends and reinforcing North America's leadership in advanced bioprocessing technologies, including single-use bioreactors.

How This Analysis Helps Clients

Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Single-use Bioreactors market report study

Market size analysis for the current single-use bioreactors market size (2025), and market forecast for 8 years (2026 to 2034)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
Key companies dominating the single-use bioreactors market.
Various opportunities available for the other competitors in the single-use bioreactors market space.
What are the top-performing segments in 2025? How these segments will perform in 2034?
Which are the top-performing regions and countries in the current single-use bioreactors market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for the single-use bioreactors market growth in the future.

Frequently Asked Questions for the Single-use Bioreactors Market

1. What is the growth rate of the single-use bioreactors market?

The single-use bioreactors market is estimated to grow at a CAGR of 17.27% during the forecast period from 2026 to 2034.

2. What is the market for single-use bioreactors?

The global single-use bioreactors market is expected to increase from USD 3,613.82 million in 2025 to USD 15,114.53 million by 2034.

3. Which region has the highest share in the single-use bioreactors market?

North America is expected to dominate the single-use bioreactors market due to its strong biopharmaceutical industry, high adoption of advanced bioprocessing technologies, and significant presence of key players such as Thermo Fisher Scientific Inc., Cytiva, and Sartorius AG. The region also benefits from substantial R&D investments, a well-established regulatory framework, and increasing demand for biologics, vaccines, and cell & gene therapies. Additionally, the growing number of CDMOs and biotechnology startups further accelerates the adoption of flexible and cost-effective single-use systems, supporting overall market growth.

4. What are the drivers for the single-use bioreactors market?

The single-use bioreactors market is being strongly driven by the combined impact of rising demand for biopharmaceuticals, cost efficiency, and technological advancements in bioprocessing. The growing need for biologics such as monoclonal antibodies, vaccines, and cell & gene therapies is increasing the demand for flexible and sterile manufacturing platforms, where single-use systems are highly effective. At the same time, these bioreactors significantly reduce capital investment and operational costs by eliminating cleaning, sterilization, and large infrastructure requirements, making them especially attractive for emerging biotech firms and CDMOs. Additionally, continuous innovations in bioprocessing, such as improved scalability, automation, and advanced sensor integration, are enhancing productivity and process control. Together, these factors are accelerating the adoption of single-use bioreactors across R&D and commercial manufacturing, thereby boosting overall market growth.

5. Who are the key players operating in the single-use bioreactors market?

Some of the key market players operating in the single-use bioreactors market include Sartorius AG, Thermo Fisher Scientific Inc., Cytiva, Merck KGaA, Eppendorf SE, ABEC Inc., PBS Biotech Inc., Cellexus International Ltd., Celltainer Biotech BV, Getinge AB, Solaris Biotech Solutions S.r.l., Pierre Guerin SAS, Meissner Filtration Products Inc., Entegris Inc., Avantor Inc., Repligen Corporation, Corning Incorporated, and others.

1. Single-use Bioreactors Market Report Introduction

1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumption

2. Single-use Bioreactors Market Executive Summary

2.1 Market at Glance

3. Single-use Bioreactors Market Key Factors Analysis

3.1 Single-use Bioreactors Market Drivers
- 3.1.1 Rising demand for biopharmaceuticals
- 3.1.2 Cost efficiency and lower capital investment
- 3.1.3 Technological advancements in bioprocessing
3.2 Single-use Bioreactors Market Restraints and Challenges
- 3.2.1 Plastic waste generation and environmental concerns
- 3.2.2 Mechanical and operational limitations
3.3 Single-use Bioreactors Market Opportunity
- 3.3.1 Digital twins and virtual bioprocess modeling

4. Impact Analysis

4.1 AI-Powered Innovations and Applications
4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

5.1 The United States
5.2 Europe
5.3 Japan
5.4 China

6. Single-use Bioreactors Market Porter's Five Forces Analysis

6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Consumers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. Single-use Bioreactors Market Assessment

7.1 By Product Type
- 7.1.1 Single-use Bioreactor Systems
  - 7.1.1.1 Up to 10 L
  - 7.1.1.2 11-100 L
  - 7.1.1.3 101-500 L
  - 7.1.1.4 501-1500 L
  - 7.1.1.5 Above 1500 L
- 7.1.2 Single-use Media Bags
  - 7.1.2.1 2D bags
  - 7.1.2.2 3D bags
- 7.1.3 Single-use Filtration Assemblies
- 7.1.4 Other Accessories
7.2 By Type
- 7.2.1 Stirred-tank Single-use Bioreactors
- 7.2.2 Wave-induced (rocking motion) Bioreactors
- 7.2.3 Others
7.3 By Cell Type
- 7.3.1 Mammalian
- 7.3.2 Bacterial
- 7.3.3 Others
7.4 By Molecule Type
- 7.4.1 Monoclonal antibodies (mAbs)
- 7.4.2 Vaccines
- 7.4.3 Recombinant proteins
- 7.4.4 Others
7.5 By Application
- 7.5.1 Research & Development (R&D)
- 7.5.2 Bioproduction / Commercial Manufacturing
7.6 By End-Users
- 7.6.1 Pharmaceutical & biopharmaceutical companies
- 7.6.2 Contract Research Organizations (CROs)
- 7.6.3 Contract Development & Manufacturing Organizations (CDMOs/CMOs)
- 7.6.4 Academic & Research Institutes
7.7 By Geography
- 7.7.1 North America
  - 7.7.1.1 United States Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.1.2 Canada Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.1.3 Mexico Single-use Bioreactors Market Size in USD million (2023-2034)
- 7.7.2 Europe
  - 7.7.2.1 France Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.2.2 Germany Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.2.3 United Kingdom Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.2.4 Italy Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.2.5 Spain Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.2.6 Rest of Europe Single-use Bioreactors Market Size in USD million (2023-2034)
- 7.7.3 Asia-Pacific
  - 7.7.3.1 China Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.3.2 Japan Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.3.3 India Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.3.4 Australia Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.3.5 South Korea Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.3.6 Rest of Asia-Pacific Single-use Bioreactors Market Size in USD million (2023-2034)
- 7.7.4 Rest of the World (RoW)
  - 7.7.4.1 Middle East Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.4.2 Africa Single-use Bioreactors Market Size in USD million (2023-2034)
  - 7.7.4.3 South America Single-use Bioreactors Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Single-use Bioreactors Market Company and Product Profiles

10.1 Sartorius AG
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Product Listing
- 10.1.5 Entropy
10.2 Thermo Fisher Scientific Inc.
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Listing
- 10.2.5 Entropy
10.3 Cytiva
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Listing
- 10.3.5 Entropy
10.4 Merck KGaA
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Listing
- 10.4.5 Entropy
10.5 Eppendorf SE
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Listing
- 10.5.5 Entropy
10.6 ABEC Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Listing
- 10.6.5 Entropy
10.7 PBS Biotech Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Listing
- 10.7.5 Entropy
10.8 Cellexus International Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Listing
- 10.8.5 Entropy
10.9 Celltainer Biotech BV
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Listing
- 10.9.5 Entropy
10.10 Getinge AB
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Listing
- 10.10.5 Entropy
10.11 Solaris Biotech Solutions S.r.l.
- 10.11.1 Company Overview
- 10.11.2 Company Snapshot
- 10.11.3 Financial Overview
- 10.11.4 Product Listing
- 10.11.5 Entropy
10.12 Pierre Guerin SAS
- 10.12.1 Company Overview
- 10.12.2 Company Snapshot
- 10.12.3 Financial Overview
- 10.12.4 Product Listing
- 10.12.5 Entropy
10.13 Meissner Filtration Products Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Snapshot
- 10.13.3 Financial Overview
- 10.13.4 Product Listing
- 10.13.5 Entrophy
10.14 Entegris Inc.
- 10.14.1 Company Overview
- 10.14.2 Company Snapshot
- 10.14.3 Financial Overview
- 10.14.4 Product Listing
- 10.14.5 Entrophy
10.15 Avantor Inc.
- 10.15.1 Company Overview
- 10.15.2 Company Snapshot
- 10.15.3 Financial Overview
- 10.15.4 Product Listing
- 10.15.5 Entrophy
10.16 Repligen Corporation
- 10.16.1 Company Overview
- 10.16.2 Company Snapshot
- 10.16.3 Financial Overview
- 10.16.4 Product Listing
- 10.16.5 Entrophy
10.17 Corning Incorporated
- 10.17.1 Company Overview
- 10.17.2 Company Snapshot
- 10.17.3 Financial Overview
- 10.17.4 Product Listing
- 10.17.5 Entrophy